| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.67 | 0.00 (0.00%) | 3.00 - 8.25 | 8.0 (Below Avg) |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 5.67 |
| Day's Range | -- - -- |
| Market Cap | 229.6M |
| Avg Volume (10 Day) | 509.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.7 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Anacor Pharmaceuticals Reports First Quarter 2013 Financial Results
Business Wire - Thursday 05/09/2013 4:01 PM ET
Anacor Pharmaceuticals Announces First Quarter 2013 Financial Results Conference Call and Webcast
Business Wire - Tuesday 05/07/2013 4:01 PM ET
Valeant Pharmaceuticals Provides Efinconazole Update
PR Newswire - Thursday 05/02/2013 8:14 PM ET
Anacor Pharmaceuticals Provides Update Regarding Arbitration With Valeant Pharmaceuticals
Business Wire - Thursday 05/02/2013 6:00 PM ET
Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Over-Allotment Option
Business Wire - Wednesday 05/01/2013 5:00 PM ET
Anacor Pharmaceuticals Prices $20 Million Public Offering of Common Stock
Business Wire - Friday 04/26/2013 9:00 AM ET
| ANAC | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -51.10% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -1.68 | |
| Earnings Yield | -- | |
| Price/Sales | 22.89 |
| Company | Last | Change |
|---|---|---|
| Cornerstone Therapeutics Inc | 8.54 | 0.00% |
| Oncolytics Biotech Inc | 2.72 | 0.00% |
| Peregrine Pharmaceuticals Inc | 1.66 | 0.00% |
| BioTime Inc | 4.19 | 0.00% |
| OvaScience Inc | 12.15 | 0.00% |
Data is delayed by at least 15 min.